登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：601607 证券简称：上海医药 编号：临2026-001 上海医药集团股份有限公司 关于2019年A股股票期权激励计划预留股票期权第三个行权期2025年第四季度自主行权结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 上海医药集团股份有限公司（以下简称"上海医药"或"公司"）2019年A股股票期权激励计划（"本次股 权激励计划"）预留股票期权第三个行权期可行权的股票期权数量680,000份，行权期自2025年2月8日起 至2026年2月7日止。 ● 本次行权股票数量：2025年第四季度，公司预留股票期权第三个行权期激励对象未行权。 一、本次股权激励计划已履行的相关审批程序 1、2019年9月30日，公司召开第七届董事会第五次会议及第七届监事会第三次会议，审议通过了《关于 2019年股票期权激励计划（草案）及其摘要的议案》（以下简称"《股票期权激励计划（草案）》"）、 《关于2019年股票期权激励计划实施考核管理办法的议案》（以下简称 ...

Core Points - The announcement details the results of the third exercise period for the stock option incentive plan of Shanghai Pharmaceuticals, indicating that no options were exercised during the second quarter of 2025 [4][11] - The total number of stock options available for the third exercise period is 680,000, with the exercise period running from February 8, 2025, to February 7, 2026 [4][11] - The company has followed all necessary approval procedures for the stock option incentive plan, including independent opinions from directors and the supervisory board [2][3][5] Approval Process - The company’s board approved the stock option incentive plan and its management measures, with independent directors providing their opinions and the supervisory board conducting necessary checks [2][3][5] - The plan was initially approved by the State-owned Assets Supervision and Administration Commission [1][2] Exercise Details - As of the second quarter of 2025, the number of individuals eligible to exercise the options is 20, but none have exercised their options [7][11] - The stock options are to be issued as ordinary shares (A-shares) to the incentive targets [7][9] Impact on Financials - The lack of exercised options during the third exercise period has not had a significant impact on the company's financial status or operating results as of the end of the second quarter of 2025 [11]